| Autor: |
Kate T. Murphy, Kristy Swiderski, James G. Ryall, Jonathan R. Davey, Hongwei Qian, Séverine Lamon, Victoria C. Foletta, Jennifer Trieu, Annabel Chee, Suzannah J. Read, Timur Naim, Paul Gregorevic, Gordon S. Lynch |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
JCSM Rapid Communications, Vol 5, Iss 1, Pp 102-116 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2617-1619 |
| DOI: |
10.1002/rco2.50 |
| Popis: |
Abstract Background Cachexia is a debilitating complication of cancer characterized by progressive wasting and weakness of skeletal muscles that reduces quality of life and can compromise survival. Many anticancer treatments, such as chemotherapy, also cause muscle wasting, which impairs the response to treatment. Given that many cancer patients present with cachexia at the initiation of treatment, we investigated whether cachectic mice were susceptible to chemotherapy‐induced muscle wasting and to investigate contributing mechanisms, including the dysregulation of microRNAs (miRs). Methods Cachectic colon‐26 (C‐26) tumour‐bearing mice were given 5‐fluourouracil (5‐FU) chemotherapy or vehicle treatment and analysed for muscle mass, fibre size and composition, and miR expression. Mechanisms were validated in vitro using C2C12 cell culture and miR mimics and inhibitors and were confirmed in vivo by injecting muscles of 5‐FU‐treated cachectic mice with recombinant adeno‐associated viral (rAAV) vectors encoding a miR sponge. Results In cachectic tumour‐bearing mice, 5‐FU chemotherapy exacerbated the loss of skeletal muscle mass compared with vehicle treatment (by −12% to −20%, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text